Nano Research

ISSN 1998-0124 CN 11-5974/O4
https://doi.org/10.1007/s12274-022-5257-7

Erratum to: Boosting SN38-based oral chemotherapy to combine reduction-bioactivated structured lipid-mimetic prodrug with ascorbic acid

Helin Wang[1,§], Qi Lu[1,§], Yifan Miao[1], Jiaxuan Song[1], Mingyang Zhang[1], Haotian Zhang[2], Zhonggui He[1], Zixuan Wang[1], Chutong Tian[1] (✉), and Jin Sun[1] (✉)

[1] *Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China*
[2] *School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China*
[§] *Helin Wang and Qi Lu contributed equally to this work.*

Erratum to

Nano Research 2022, 15(10): 9092–9104
https://doi.org/10.1007/s12274-022-4544-7

Figure 9 was unfortunately mistakenly typeset. This error did not affect any of the conclusions from the published paper.

Instead of



Figure 9 *In vivo* antitumor efficacy of 4T1 tumor. (a) The coadministration strategy of SN38 structured lipid prodrugs and ascorbic acid to 4T1 tumor-bearing mice. (b) *In vivo* antitumor activity of prodrug against 4T1 *in-situ* tumors. (c) Body weight change in each group. (d) The images of tumors at Day 10. G1:Saline; G2:SN38 solution, p.o., 10 mg/kg; G3:SN38 lipid formulation, p.o., 10 mg/kg; G4:SN38 solution, i.v., 5 mg/kg; G5:SN38-C-C-OcA lipid formulation, p.o., 10 mg/kg; G6:SN38-C-C-OcA lipid formulation, p.o., 10 mg/kg + ASC, i.p., 400 mg/kg; G7:SN38-S-S-OcA lipid formulation, p.o., 10 mg/kg and G8:SN38-S-S-OcA lipid formulation, p.o., 10 mg/kg + ASC, i.p., 400 mg/kg. (e) Tumor burden for each group. ($n = 5$). *$P < 0.05$ and ****$P < 0.0001$ versus control.

Address correspondence to Chutong Tian, tianct_spu@126.com; Jin Sun, sunjin@syphu.edu.cn

It should be changed to



Figure 9 *In vivo* antitumor efficacy of 4T1 tumor. (a) The coadministration strategy of SN38 structured lipid prodrugs and ascorbic acid to 4T1 tumor-bearing mice. (b) *In vivo* antitumor activity of prodrug against 4T1 *in-situ* tumors. (c) Body weight change in each group. (d) The images of tumors at Day 10. G1:Saline; G2:SN38 solution, p.o., 10 mg/kg; G3:SN38 lipid formulation, p.o., 10 mg/kg; G4:SN38 solution, i.v., 5 mg/kg; G5:SN38-C-C-OcA lipid formulation, p.o., 10 mg/kg; G6:SN38-C-C-OcA lipid formulation, p.o., 10 mg/kg + ASC, i.p., 400 mg/kg; G7:SN38-S-S-OcA lipid formulation, p.o., 10 mg/kg and G8:SN38-S-S-OcA lipid formulation, p.o., 10 mg/kg + ASC, i.p., 400 mg/kg. (e) Tumor burden for each group. ($n = 5$). *$P < 0.05$ and ****$P < 0.0001$ versus control.

The online version of the original article can be found at
https://doi.org/10.1007/s12274-022-4544-7